Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation

To investigate the incidence, risk factors and survival of bronchiolitis obliterans syndrome (BOS) in patients who had undergone haplo-hematopoietic stem cell transplantation (haplo-HSCT) . This study retrospectively analyzed clinical data of 444 consecutive patients who underwent haplo-HSCT and survived at least 100 days after transplantation in the First Affiliated Hospital of Soochow University between January 2013 and December 2015. By the end of follow-up on January 1, 2018, 25 patients (5.63%) had BOS (BOS group) . The median onset time of BOS was 448 (165-845) d post transplantation, the 1-year, 2-year and 3-year cumulative incidence of BOS was 1.6% (95% 1.5%-1.6%) , 4.8% (95% 4.7%-4.8%) and 5.8% (95% 5.7%-5.8%) , respectively. Among patients with chronic graft-versus-host disease (cGVHD) , the cumulative incidence at the same intervals was 2.8% (95% 2.7%-2.8%) , 9.5% (95% 9.4%-9.5%) and 11.5% (95% 11.4%-11.6%) , respectively. In the multivariate analysis, the risk factors for BOS were high-risk primar